Device Trial Radar · NCT04076566
Malignant Ascites Alfapump® Study
Last checked: Nov 19, 2026Latest source record: Aug 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
May 31, 2020
Primary completion
Dec 2021
Study completion Mar 2022
Sponsor
- Lead sponsor
- Sequana Medical N.V.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 3, 2019
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
ProMAS is a prospective post-marketing, single-arm study to assess performance and safety of the Alfapump® system in the treatment of patients with malignant ascites. The study aims to enroll 40 patients in up to 8 sites in Europe.
Conditions
- Malignant Ascites
Interventions
alfapump systemDevice
active implantable device for treatment of malignant ascites
Primary outcomes
What the sponsor says the trial is designed to measure.
- Monthly therapeutic paracentesis frequency up to 3 monthsTime frame: 3 months post-implantation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hammersmith Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.